It beat convincingly on both the top and bottom lines. For its first quarter of this year, AbbVie's net revenue was $13.3 billion, representing a sturdy 8% improvement on a year-over-year basis.

Rob Stothard / Bloomberg via Getty Images AbbVie's first-quarter sales and adjusted earnings per share topped estimates. The drugmaker lifted its full-year adjusted EPS forecast by 10 cents.

AbbVie's first-quarter sales and adjusted earnings per share topped estimates. The drugmaker lifted its full-year adjusted EPS forecast by 10 cents. However, the company noted its business could ...

Delivers First-Quarter Net Revenues of $13.343 Billion, an Increase of 8.4 Percent on a Reported Basis or 9.8 Percent on an Operational Basis "AbbVie's first-quarter results were well ahead of our ...

AbbVie (NYSE:ABBV) is scheduled to announce its earnings on Friday, April 25, 2025. Currently, the company holds a market capitalization of $307 billion. Over the past twelve months, AbbVie ...

Plus, AbbVie’s top-selling drug, Skyrizi, is made in the U.S., the CEO added. Nevertheless, AbbVie is bracing for potential near-term headwinds if pharmaceutical tariffs touch down, said CFO Reents.

NORTH CHICAGO, Ill. (AP) — NORTH CHICAGO, Ill. (AP) — AbbVie Inc. (ABBV) on Friday reported first-quarter profit of $1.29 billion. The North Chicago, Illinois-based company said it had net ...

AbbVie Inc. raised its profit outlook for the year on better-than-expected sales from newer autoimmune treatments, but warned its forecast doesn’t take into account any potential changes in ...

Skyrizi and Rinvoq use in gastroenterology grew over 40% year-over-year. Cantor gave AbbVie an Overweight rating with a $210 price target. Feel unsure about the market’s next move? Copy trade ...

AbbVie is hoping to extend its range of neurotoxin-based pharma and cosmetic products with trenibotulinumtoxinE (TrenibotE), a short-acting successor to its blockbuster Botox brand, that has just ...

AbbVie's Q1 EPS of $2.46 beat estimates; sales rose 8.4% to $13.34 billion, topping consensus of $12.92 billion. Skyrizi and Rinvoq sales surged 70.5% and 57.2%, while Humira dropped 50.6%. Feel ...